#ECTRIMS2021 – Ublituximab Better Than Aubagio at Reducing Disability

#ECTRIMS2021 – Ublituximab Better Than Aubagio at Reducing Disability

309406

#ECTRIMS2021 – Ublituximab Better Than Aubagio at Reducing Disability

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. The investigational anti-CD20 antibody ublituximab outperformed Aubagio (teriflunomide) in reducing disability and slowing brain shrinkage in people with active, relapsing forms of multiple sclerosis (MS), according to new results from the two Phase 3 ULTIMATE clinical…

You must be logged in to read/download the full post.